Literature DB >> 17911432

Association of the 5A/6A promoter polymorphism of the MMP-3 gene with the radiographic progression of rheumatoid arthritis.

Petr Nemec1, Monika Pavkova-Goldbergova, Jindra Gatterova, Anna Vasku, Miroslav Soucek.   

Abstract

Matrix metalloproteinases (MMPs) as a family of zinc-dependent endopeptidases have been involved in remodeling the extracellular matrix (ECM) in rheumatoid arthritis (RA). In RA patients synovial fluid and serum include enhanced levels of MMP-3. The 5A/6A polymorphism in the MMP-3 gene promoter can contribute to the severity of RA on account of a higher promoter activity of the 5A allele in vitro. The aim of the study was to associate the 5A/6A polymorphism of the MMP-3 gene with radiographic progression of RA. A total of 128 RA patients according to the ACR criteria were available for the study. Radiographs of both hands, obtained from all RA patients, were scored using the modified Sharp/van der Heijde method and the Steinbrocker method. The total Sharp score (TSS) and the annual radiographic progression rate (TSS/year) were calculated. Significant association with the 5A/6A polymorphism was found between patients with TSS/year <or= 1.00 and those with TSS/year > 1.00 in allelic frequencies (Pa = 0.046) and also in genotype distribution (Pg = 0.04). Compared to other genotypes the prevalence of 5A/5A genotype was lower within patients with TSS/year <or= 1.00 (odds ratio [OR] = 0.2; 95% confidence interval [CI] 0.04-0.85; P = 0.01). Also, in comparison to genotypes 5A/6A and 5A/5A, the prevalence of 6A/6A genotype was higher within patients with nonerosive RA (OR = 2.65; 95% CI 1.03-6.83, P = 0.02). Results obtained in this study provide the evidence of an association of the 5A/6A promoter polymorphism of the MMP-3 gene to the radiographic progression of RA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911432     DOI: 10.1196/annals.1423.019

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Relationship of long-term prognosis to MMP and TIMP polymorphisms in patients after ST elevation myocardial infarction.

Authors:  Monika Pavkova Goldbergova; Jiri Jarkovsky; Jolana Lipkova; Simona Littnerova; Martin Poloczek; Jindrich Spinar; Lenka Kubkova; Krystyna Kluz; Petr Kala; Jan Manousek; Anna Vasku; Jiri Parenica
Journal:  J Appl Genet       Date:  2017-01-18       Impact factor: 3.240

Review 2.  [Possibilities and limitations of genomic analyses in rheumatoid arthritis].

Authors:  S Drynda; J Kekow
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

3.  The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis.

Authors:  M I Danila; A O Westfall; K Raman; L Chen; R J Reynolds; L B Hughes; D K Arnett; G McGwin; A J Szalai; D M van der Heijde; D Conn; L F Callahan; L W Moreland; S L Bridges
Journal:  Genes Immun       Date:  2015-07-30       Impact factor: 2.676

4.  Matrix metalloproteinase gene polymorphisms in patients with rheumatoid arthritis.

Authors:  Sabrina Scherer; Thais Barboza de Souza; Juliana de Paoli; Claiton Viegas Brenol; Ricardo Machado Xavier; João Carlos Tavares Brenol; José Artur Chies; Daniel Simon
Journal:  Rheumatol Int       Date:  2009-06-06       Impact factor: 2.631

5.  Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.

Authors:  Sudha Visvanathan; Mahboob U Rahman; Edward Keystone; Mark Genovese; Lars Klareskog; Elizabeth Hsia; Michael Mack; Jacqui Buchanan; Michael Elashoff; Carrie Wagner
Journal:  Arthritis Res Ther       Date:  2010-11-17       Impact factor: 5.156

6.  Lack of association of matrix metalloproteinase-3 gene polymorphism with susceptibility to rheumatoid arthritis: a meta-analysis.

Authors:  Zhitao Feng; Guochao He; Zhuanghong Chen; Zhengzhi Wu; Juan Li
Journal:  BMC Musculoskelet Disord       Date:  2014-11-18       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.